Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00778765
Recruitment Status : Completed
First Posted : October 23, 2008
Last Update Posted : October 23, 2008
Information provided by:
Ranbaxy Inc.

Brief Summary:
To compare the single-dose oral bioavailability of metformin HCI liquid 500 mg/5 mL of Ranbaxy with Glucophage® 1000 mg tablets of Bristol-Myers, USA following administration of a 1000 mg dose in healthy, adult, male and female volunteers under fasting conditions

Condition or disease Intervention/treatment Phase
Healthy Drug: 400 mg Gabapentin Capsules Not Applicable

Detailed Description:
This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult volunteers and 2 alternates. All 26 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 36-hour blood draw. Single oral 400 mg doses were separated by a washout period of 7 days A total of 24 healthy adult volunteers and 2 alternates (17 males and 9 non-pregnant females) enrolled in and completed the clinical phase of the study

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fed Conditions
Study Start Date : September 2002
Actual Primary Completion Date : October 2002
Actual Study Completion Date : December 2002

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
400 mg Gabapentin Capsules of Ranbaxy
Drug: 400 mg Gabapentin Capsules
Active Comparator: 2
Neurontin® 400 mg Gabapentin Capsules
Drug: 400 mg Gabapentin Capsules

Primary Outcome Measures :
  1. Bioequivalence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy adult male or female volunteers, 18-55 years of age
  2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
  3. Medically healthy subjects with clinically normal laboratory profiles
  4. Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable birth control methods:

    • surgically sterile (bilateral tubal ligation, hysterectomy bilateral oophorectomy) 6 months minimum
    • IUD in place for at least 3 months
    • barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the start of the study and throughout the study
    • surgical sterilization of the partner (vasectomy for 6 months minimum)
    • hormonal contraceptives for at least 3 months prior to the start of the study

    Other birth control methods may be deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years will be eligible.

  5. Voluntarily consent to participate in the study.

Exclusion Criteria:

Subject candidates must not be enrolled in the study if they meet any of the following criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  2. In addition, history or presence of:

    • alcoholism or drug abuse within the past 2 years
    • hypersensitivity or idiosyncratic reaction to anticonvulsants
  3. Female subjects who are pregnant or lactating
  4. Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dose
  5. Subjects who, through completion of the study, would have donated in excess of:

    • 500 mL of blood in 14 days, or
    • 500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator)
    • 1000 mL of blood in 90 days
    • 1250 mL of blood in 12 days
    • 1500 mL of blood in 180 days
    • 2000 mL of blood in 270 days
    • 2500 mL of blood in I year
  6. Subjects who have participated in another clinical trial within 28 days prior to the first dose

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00778765

Canada, Quebec
MDS Pharma Services
Saint-Laurent,, Quebec, Canada
Sponsors and Collaborators
Ranbaxy Laboratories Limited

Additional Information:
Responsible Party: Dr. tausif Monif, Ranbaxy Research Labs Identifier: NCT00778765     History of Changes
Other Study ID Numbers: AA01820
First Posted: October 23, 2008    Key Record Dates
Last Update Posted: October 23, 2008
Last Verified: October 2008

Keywords provided by Ranbaxy Inc.:
Bioequivalence gabapentin fed conditions

Additional relevant MeSH terms:
gamma-Aminobutyric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents